Results 141 to 150 of about 274,173 (312)

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

The Maine Cancer Genomics Initiative: Implementing a Community Cancer Genomics Program Across an Entire Rural State. [PDF]

JCO Precis Oncol, 2023
Rueter J, Anderson EC, Graham LC, Antov A, Helbig P, Gaitor L, Bourne J, Edelman E, Reed EK, Reddi HV, Mockus S, DiPalazzo J, Lu-Emerson C, Inhorn R, Sinclair SJ, Thomas CA, Brooks PL, Rasmussen K, Han P, Liu ET, MCGI Working Group.   +20 more
europepmc   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Comparative genomic profiling identifies targetable brain metastasis drivers in non-small cell lung cancer [PDF]

, 2022
Marcin Nicoś, Luuk Harbers, Enrico Patrucco, Maximilian Kramer‐Drauberg, Xiaolu Zhang, Claudia Voena, Anna Kowalczyk, Aleksandra Bożyk, Rafał Pęksa, Bożena Jarosz, Justyna Szumiło, Michele Simonetti, Monika Żuk, Bartosz Wasąg, Katarzyna Reszka, Renata Duchnowska, Janusz Milanowski, Roberto Chiarle, Magda Bienko, Paweł Krawczyk, Jacek Jassem, Chiara Ambrogio, Nicola Crosetto   +22 more
openalex   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Supplemental Figure S3 from <i>KRAS</i> Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine

, 2023
Michelle L. Stewart, Pablo Tamayo, Andrew Wilson, Stephanie Wang, Yun Min Chang, Jong W. Kim, Dineo Khabele, Alykhan F. Shamji, Stuart L. Schreiber   +8 more
openalex   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Prognostic significance of lymphovascular invasion in colorectal cancer and its association with genomic alterations

, 2019
Huihong Jiang, Zhiyong Zhang, Xiaoyan Wang, Xuan Tang, Hailong Liu, Aili Wang, Huaguang Li, Erjiang Tang, Moubin Lin   +8 more
openalex   +2 more sources

Supplementary Table S5 from Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer

, 2023
Elizabeth H. Stover, Maria B. Baco, Ofir Cohen, Yvonne Y. Li, Elizabeth L. Christie, Mukta Bagul, Amy Goodale, Yenarae Lee, Sasha Pantel, Matthew G. Rees, Wei Guo, Adam Presser, Maya K. Gelbard, Weiqun Zhang, Ioannis K. Zervantonakis, Patrick Bhola, Jeremy Ryan, Jennifer L. Guerriero, Joan Montero, Felice J. Liang, Andrew D. Cherniack, Federica Piccioni, Ursula A. Matulonis, David D.L. Bowtell, Kristopher A. Sarosiek, Anthony Letai, Levi A. Garraway, Cory M. Johannessen, Matthew Meyerson   +28 more
openalex   +1 more source

Supplementary Table S3 from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition [PDF]

, 2023
Carolina Pereira, Pol Giménez‐Xavier, Eva Pros, María J. Pajares, Massimo Moro, Antonio Gomez, A. Bañón Navarro, Enric Condom, Sebastián Morán, Gonzalo Goméz-López, Osvaldo Graña‐Castro, Miriam Rubio-Camarillo, Alex Martínez‐Martí, Jun Yokota, Julián Carretero, José M. Galbis, Ernest Nadal, David G. Pisano, Gabriella Sozzi, Enriqueta Felip, Luis M. Montuenga, Luca Roz, Alberto Villanueva, Montse Sánchez‐Céspedes   +23 more
openalex   +1 more source